Metalyse Adverse Reactions

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Full Prescribing Info

Adverse Reactions

As with other thrombolytic agents, haemorrhage is the most common adverse reaction associated with the use of METALYSE. Haemorrhage at any site or body cavity can occur and may result in life-threatening situations, permanent disability or death.
The type of haemorrhage associated with thrombolytic therapy can be divided into two broad categories: superficial bleeding, normally from injection sites; internal bleeding at any site or body cavity.
With intracranial haemorrhage neurological symptoms such as somnolence, aphasia, hemiparesis, convulsion may be associated.
The frequencies given as follows are based on corresponding occurrences in three clinical trials (ASSENT 2, ASSENT 3 and ASSENT 4) involving 13,897 patients treated with METALYSE for myocardial infarction.
Table 5 displays the frequency of adverse reactions. (See Table 5.)

Click on icon to see table/diagram/image

View ADR Monitoring Form

Metalyse Adverse Reactions

tenecteplase

Manufacturer:

Boehringer Ingelheim

Distributor:

DKSH